2025年第二季度总收入为1.1亿美元,同比增长9%;重申了2025年5.60亿至5.90亿美元的全年收入指引艾加莫德在第二季度的患者使用量创下纪录;更新的中国重症肌无力诊疗指南提升了艾加莫德作为全身型重症肌无力(gMG)急性期和维持期治疗方案的地位2025年第二季度经营亏损为5,490万美元,同比收窄28%,调整后的经营亏损1收窄37%至3,420万美元;正稳步迈向2025年第四季度实现盈利1的...
Source Link2025年第二季度总收入为1.1亿美元,同比增长9%;重申了2025年5.60亿至5.90亿美元的全年收入指引艾加莫德在第二季度的患者使用量创下纪录;更新的中国重症肌无力诊疗指南提升了艾加莫德作为全身型重症肌无力(gMG)急性期和维持期治疗方案的地位2025年第二季度经营亏损为5,490万美元,同比收窄28%,调整后的经营亏损1收窄37%至3,420万美元;正稳步迈向2025年第四季度实现盈利1的...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.